+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
E

Actively Recruiting

Researchers are evaluating the side effects and effectiveness of adding inotuzumab ozogamicin to frontline chemotherapy for young adults aged 18 to 39 with newly diagnosed B acute lymphoblastic leukemia, a type of blood cancer. Inotuzumab ozogamicin is a targeted therapy that delivers a chemotherapy drug directly to cancer cells. This phase III trial aims to confirm the safety and improve event-free survival compared to standard pediatric-inspired chemotherapy. Participants receive a combination of chemotherapy drugs in several treatment courses, including remission induction, remission consolidation, interim maintenance, delayed intensification, and maintenance therapy. Those in the experimental group receive inotuzumab ozogamicin intravenously on specific days alongside chemotherapy, with additional treatments like blinatumomab given if minimal residual disease is detected. Procedures such as bone marrow biopsies and imaging are performed throughout. Participants will be closely monitored through blood tests, bone marrow samples, imaging scans, and symptom assessments. Researchers will measure outcomes like event-free survival, disease-free survival, overall survival, response rates, and adverse events over several years. After treatment, participants are followed regularly for up to 10 years to assess long-term effects and survival.

Age: 18Years - 39YearsAll GendersPhase 3
460 locations
S

Actively Recruiting

Researchers are studying patients with high-risk smoldering multiple myeloma to compare how well lenalidomide and dexamethasone work with or without daratumumab in treating this condition. The trial aims to assess overall survival, progression-free survival, response rates, safety, and quality of life among participants, while also exploring treatment adherence and disease markers over time. Participants are randomly assigned to one of two groups. One group receives daratumumab intravenously on a set schedule along with oral lenalidomide daily and oral dexamethasone on specified days in 28-day treatment cycles for up to 24 courses. The other group receives only oral lenalidomide and dexamethasone on a similar 28-day cycle schedule for the same duration, unless disease progression or unacceptable side effects occur. Throughout the study, participants will undergo regular assessments including blood tests, bone marrow biopsies, imaging scans, and questionnaires to monitor disease status, treatment effects, and quality of life. Follow-up visits will continue every 3 to 12 months for up to 15 years after study treatment ends to track long-term outcomes. Researchers will measure survival, symptom changes, adverse events, and minimal residual disease levels to evaluate treatment impact.

Age: 18Years +All GendersPhase 3
748 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
C

Actively Recruiting

Researchers are studying how well serum tumor marker directed disease monitoring works compared to the usual monitoring approach for patients with hormone receptor positive, HER2 negative metastatic breast cancer. This trial aims to see if monitoring patients with specific blood markers to decide when to perform scans leads to similar overall survival as the standard care. The study also explores healthcare costs and patient-reported anxiety and quality of life between these monitoring methods. Participants are randomly assigned to one of two groups. One group receives usual care with imaging at least every 12 weeks and tumor marker tests as decided by their doctor. The other group undergoes regular serum tumor marker tests every 4 to 8 weeks, and imaging is only done if these markers rise. Both groups continue their assigned monitoring until disease progression or up to 312 weeks. During the study, participants complete questionnaires about anxiety and quality of life. Researchers collect data on overall survival, healthcare costs, and patient experiences over various timeframes, including up to 312 weeks for survival and 102 weeks for patient-reported outcomes. Monitoring is consistent at facilities accessible to the study team, and participants are followed closely while on their assigned monitoring approach throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
723 locations
P

Actively Recruiting

Researchers are evaluating treatments for men with metastatic prostate cancer, a condition where cancer has spread beyond the prostate to other parts of the body. This phase III trial compares standard systemic therapy alone versus standard systemic therapy combined with definitive treatment of the primary tumor, such as prostate removal surgery or radiation therapy. The goal is to see if adding these local treatments improves survival and delays cancer progression. Participants begin with an induction period of 22 to 28 weeks receiving one of six forms of standard systemic therapy, which may include hormone therapies like goserelin or leuprolide injections, oral medications such as abiraterone or bicalutamide, or chemotherapy with docetaxel. After induction, participants are randomly assigned to continue systemic therapy alone or to receive systemic therapy plus prostatectomy within 8 weeks or radiation therapy within 4 weeks. The study includes tissue and blood sample collection for future research. Throughout the trial, participants have regular assessments including physical exams, laboratory tests measuring PSA and testosterone levels, and imaging scans to monitor disease status. Patient-reported quality of life related to urinary function, pain, and physical abilities is also evaluated over several years. After treatment, participants are followed for up to eight years to track overall survival, progression-free survival, and local symptom progression, providing a comprehensive understanding of treatment effects over time.

Age: 18Years +MALEPhase 3
338 locations
P

Actively Recruiting

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.

Age: 65Years +All GendersPhase 3
789 locations
C

Actively Recruiting

Researchers are evaluating radiation therapy options for men with high-risk prostate cancer in this phase III trial. The study compares a shorter course of stereotactic body radiation therapy SBRT, which delivers five high-dose treatments over two weeks, to the usual longer radiation therapy given over 4 to 9 weeks. The goal is to see if the shorter treatment is as effective in preventing cancer from returning as the standard therapy. Participants are randomly assigned to one of two groups the first group receives SBRT with five treatments over two weeks, and the second group undergoes external beam radiation therapy EBRT with 20 to 45 treatments over 4 to 9 weeks. Both groups may have bone scans, CT, MRI, or PETCT scans during screening and on study, and they may optionally provide blood and urine samples. This trial includes follow-up visits every six months for five years to monitor outcomes. During the study, participants will have various assessments including imaging and questionnaires to evaluate urinary, bowel, sexual function, fatigue, quality of life, and treatment burden. Researchers will track metastasis-free survival, failure-free survival, overall survival, adverse events, and patient-reported outcomes up to 15 years. The study aims to provide detailed information about the effectiveness and impact of the shorter radiation therapy compared to the usual treatment.

Age: 18Years +MALEPhase 3
436 locations